@misc{oai:repo.qst.go.jp:00070026,
 author = {Shinoto, Makoto and Yamada, Shigeru and Katou, Hirotoshi and Yasuda, Shigeo and Imada, Hiroshi and Kamada, Tadashi and Tsujii, Hirohiko and Saisho, Hiromitsu and 篠藤 誠 and 山田 滋 and 加藤 博敏 and 安田 茂雄 and 今田 浩史 and 鎌田 正 and 辻井 博彦 and 税所 宏光},
 month = {Jan},
 note = {Purpose: We examined the effect of preoperative carbon ion therapy in terms of reducing the rate of local recurrence in patients undergoing resection for adenocarcinoma of the pancreas.
Patients and Methods:  Between July 2000 and December 2002, 22 patients with preoperative pancreas cancer were enrolled into this trial. Median age was 63 years. Carbon ion therapy was given once daily, 4 days a week, for a fixed 16 fractions in 4 weeks. The dose was set to 44.8GyE and escalated to 48.0GyE at 5% increments. 
Results:All patients completed the scheduled treatment course. Three grade3 acute reactions and two grade3 late reactions occurred among 16 of the patients treated with a dose of 48.0GyE. Two grade 3 late reactions of them were estimated to be caused by carbon ion therapy. Of 22 patients, 15(68%) had resection. All tumor specimens pathologically revealed evidence of grade 2 treatment effects with significant fibrosis, hyalinization, and necrosis (Pathological grade2 is defined as a less than 33% active cancer cells.).  Remarkable antitumor effects were observed. The overall local control rates were 100% and 87% at 1 year and at 2 years of follow-up respectively. No local failure was observed in any of the 22 enrolled patients.
Conclusion: Carbon ion radiotherapy seems to be a safe and effective modality in the management of resectable pancreatic carcinoma, providing good local control and offering a survival advantage without unacceptable morbidity., 2010 Gastrointestinal Cancers Symposium},
 title = {A Phase I/II Clinical Trial of Carbon-ion Therapy for patients with preoperative pancreas cancer (Protocol 9906, 16fractions/4weeks)},
 year = {2010}
}